NCT05891821View on ClinicalTrials.gov

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Lymphoma
Interventions
DRUG

Balstilimab

An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody

Trial Locations (1)

0014

RECRUITING

Hematology Center named after prof. R. Yeolyan, Yerevan

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
lead

Immune Oncology Research Institute

OTHER

collaborator

Agenus Inc.

INDUSTRY